Retargeting T cells and immune effector cells with bispecific antibodies

This publication has 83 references indexed in Scilit:

• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
  Science, 2002
• T Cell Activation Modulates Retrovirus-Mediated Gene Expression
  Human Gene Therapy, 1998
• Release of Cytokines and Soluble Cell Surface Molecules by PBMC after Activation with the Bispecific Antibody CD3 × CD19
  Scandinavian Journal of Immunology, 1997
• Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line
  Tissue Antigens, 1996
• A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL
  Molecular Immunology, 1996
• Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevance
  Immunology Today, 1995
• CD8 T cell activation after intravenous administration of CD3 CD19 bispecific antibody in patients with non-Hodgkin lymphoma
  Cancer Immunology, Immunotherapy, 1995
• CD30‐antigen‐specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of hodgkin's lymphoma
  International Journal of Cancer, 1993
• Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
  New England Journal of Medicine, 1988
• A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
  Science, 1986